Reagents News and Research

RSS

Rheonix announces completion of $12.6 million Series A financing

Rheonix, Inc. today announced the completion of a $12.6 million Series A financing to continue development of the Rheonix CARD™ (Chemistry And Reagent Device) system. This powerful, analytic platform for the life-science industry vertically integrates all the functions of traditional molecular diagnostic instrumentation into a single system to achieve unprecedented raw sample preparation, molecular amplification and multiplex analysis.

21 Apr 2010

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

NanoString Technologies launches new miRNA assay kits

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced a unique new product for miRNA analysis that includes a multiplexed assay for profiling the human miRNA transcriptome in a single tube. The company introduced the new assay kit, which expands the applications for its nCounter® Analysis System, at the American Association for Cancer Research annual meeting.

From NanoString Technologies 20 Apr 2010

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

LifeSpan BioSciences, Inc., a leading provider of antibodies for thousands of researchers worldwide, has increased the number of validated IHC-plus™ antibodies available in its catalog to more than 3,500. With this increase, LifeSpan is well on its way to building the world's largest catalog of well characterized, IHC-validated reagent antibodies. Overall, LifeSpan has a catalog of more than 82,000 antibodies.

20 Apr 2010

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex arrays from Protein Biotechnologies.

17 Apr 2010

Stemgent, Pfizer announce collaboration and research licensing agreement

Stemgent, Inc. and Pfizer Inc. today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.

16 Apr 2010

Research may help develop simplified test for early detection of breast cancer

Researchers at the University of Arkansas are building a library of synthetically produced antibodies that can detect and rapidly validate proteins secreted by breast cancer cells. Their work will accelerate the process of developing a simple blood test for early detection of breast cancer.

16 Apr 2010

Diasorin migrates to Orange Business Services' Business VPN solution

Diasorin S.p.A., an international player in the market of in vitro diagnostics based in Saluggia (Vercelli, Italy), has migrated to Business VPN, a fully-managed, secure, global IP infrastructure from Orange Business Services connecting 12 locations in Europe, the Americas and Asia.

12 Apr 2010

TriLink partners with Cedarlane to enhance distribution of its products in Canada

TriLink BioTechnologies, has entered into an agreement with Cedarlane Corporation, a Canadian based research biotechnology company, for the sale and distribution of its modified nucleoside triphosphates, custom chemistry and oligonucleotide products.

9 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

Sigma-Aldrich, HSI sign distribution agreement for patented stable isotope labeled synthetic reagents

Sigma-Aldrich® announced today that it has signed an agreement with New Mexico Highlands University through its licensee, Highlands Stable Isotope Corp., to exclusively distribute a novel set of patented stable isotope labeled synthetic reagents.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the fourth quarter and full year ended December 31, 2009.

31 Mar 2010

Siemens Healthcare Diagnostics announces new contract with Premier Purchasing Partners

Siemens Healthcare Diagnostics announces a new three-year contract with Premier Purchasing Partners, L.P., the group purchasing unit of Premier Inc., that includes Siemens powerful integrated diagnostic systems, several specialty diagnostic instruments, and a comprehensive menu of diagnostic tests for Premier's more than 2,300 member hospitals and 64,000 additional healthcare sites.

29 Mar 2010

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced that it has added 2,200 new Prestige Antibodies® powered by Atlas Antibodies to its industry-leading portfolio.

From Atlas Antibodies AB 29 Mar 2010

Market update on CBI's planned acquisition of Shanghai-based GL-Biochem

Commonwealth Biotechnologies, Inc. is pleased to provide this market update about its planned acquisition of Shanghai-based GL-Biochem and its associated businesses, one of the largest global suppliers of research-grade peptide products and peptide reagents.

27 Mar 2010

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Inverness Medical Deutschland GmbH today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in the key European markets of Germany, Austria and Switzerland.

26 Mar 2010

Fluidigm, SABiosciences partner to create pathway-focused gene expression panels for BioMark system

Fluidigm Corporation and SABiosciences (a QIAGEN Company) today announced that they have teamed up to create over 100 pathway-focused gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System for Genetic Analysis. These kits are named the RT² Profiler™ PCR Arrays for the Fluidigm BioMark system.

26 Mar 2010

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids.

25 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010